Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — Q1 2007 Earnings Presentation
12 slides from Simulations Plus's earnings presentation, Jan 17, 2007
Slide 1: Introduction and Welcome
Introduction and Welcome •Introduction and welcome •Why conference call now? -High interest and activity -November volume 432,000 shares -December volume 1.6 MM shares, most after December 14 -January volume to date ~1.8 MM shares (9 trading days) -Record close at $7.05 on Friday •Agenda -1Q 2007 su
Slide 2: 1Q 2007 Summary
1Q 2007 Summary •Gross revenues = $1.456 MM (up 77.8%) -Pharmaceutical revenues up 314% •SG&A = $757,000 (up 20.4%) -As a percent of sales, down from 177% to 53% •R&D = $317,000 ($133,000 capitalized, $184,000 expensed) -1Q FY06 $460,000, with $363,000 capitalized and $246,000 expensed) •Gross profi
Slide 3: Progress: ADMET Predictor/ADMET Modeler
Progress •ADMET Predictor/ADMET Modeler -Combined into one program and released as ADMET Predictor 2.0 in September -Combined capability expected to increase appeal in a very competitive market -Continues to enjoy reputation as most accurate structure-property prediction program currently available
Slide 4: Progress: ClassPharmer and DDDPlus
Progress -2 •ClassPharmer -Japan NIHS (equivalent of FDA) signed 5-year license -Version 4.2 released in November •Pipeline Pilot integration •Improvements in classification algorithms, speed, and number of molecules that can be handled in a single run •DDDPlus -Version 2.0 released in November -Sal
Slide 5: Progress: GastroPlus
Progress -3 •GastroPlus -Version 5.2 released in November -Continues to be the “Gold Standard” in the industry for its market niche -FDA license announced during the 2ndquarter -Ongoing contract effort at one FTE with large pharmacontinuing to improve PBPK
Slide 6: Contract studies
Progress -4 •Contract studies -Increasing demand for consulting services -2 studies in FY05, 3 in FY06, 5 already this year -Industry appears to have a shortage of expertise in simulation and modeling personnel as evidenced by employment ads we see almost daily
Slide 7: Words+ subsidiary
Progress -5 •Words+ subsidiary -Consulting marketing and sales manager very active -New California sales rep added as employee -Preparations for release of Windows Vista underway with Microsoft assistance
Slide 8: Strategy Going Forward
Strategy Going Forward •Expand product line and services -Pharmaceutical software •Respond to customer requests for enhancements to existing products •New product development -Completion of MembranePlus™ -Others not yet public •Continue seeking opportunities to partner or acquire new products -Pharm
Slide 9: Guidance
Guidance •Guidance provided in November conference call was to expect increase in total revenues of at least $1 million •As of today, pharmaceutical revenues are already up over $980,000, after only 1 ½ quarters •We expect to issue revised guidance after the end of the second quarter
Slide 10: Summary
Summary •Company is strong and growing -focus is on further growth •No debt, strong cash position •Strong cash flow and consistent growth in shareholders’ equity are the indicators of demonstrated growth •Dedicated and extremely talented workforce working to grow the product lines in both businesses
Slide 11: Summary
¥. Summary Company is strong and growing — focus is on further growth No debt, strong cash position Strong cash flow and consistent growth in shareholders” equity are the indicators of demonstrated growth Dedicated and extremely talented workforce working to grow the product lines in both businesses
Slide 12: Questions?
Questions? simulations plus, inc. g